Introducing the Langerhans Cell Targeted Delivery System

LC-TDS

Contributing to precision medicine.

LC-TDS

LC-TDS: The Langerhans Cell Targeted Delivery System

Easy-to-use, without injuries and highly specific – a minimal-invasive application of targeted nanoparticles.

The immune system protects our body from harmful invaders, like viruses and bacteria. A central role play dendritic cells (DCs) for recognizing these invaders and teaching other immune cells to fight them. At the same time, DCs are also responsible for tolerating the body’s own structures (autoantigens) – a delicate “orchestra” of immune modulation!

Cutanos will harness the role of DCs to provide therapies for allergies, autoimmune diseases and cancer as well as vaccines against infectious diseases.

We use a system called LC-TDS, which presents antigens to the immune system through only one specific DC type: Langerhans cells (LCs). Depending on the state of the LCs, the immune response can induce tolerance or provide vaccination effects. Through our targeted delivery approach, we aim for safe immune profiles and significant dose sparing. The LC-TDS differs from other immunomodulating technologies due to a modular design allowing adaptation for different applications and high compatibility with other technologies. Another major advantage is the injury-free administration via the skin, increasing application safety and patients‘ compliance.

Why are Langerhans Cells special amongst other Dendritic cells?

  • Reside in the epidermis, the outermost layer of the skin
  • Express specific surface markers and receptors that enable them to recognize and respond to a wide range of antigens
  • Ability to induce tolerance to self-antigens
  • Regulate T cell responses (can either activate or suppress T cell responses)

What makes LCs promising targets for Immune therapies?

  •  Accessible through the skin
  • Ideal for targeted drug delivery due to their unique properties and ability to recognize specific antigens
  • Can be manipulated to induce tolerance in autoimmune diseases and allergies, or to enhance immune responses against cancer and infectious diseases
  • High potential for developing vaccines and immunotherapies that are safe and effective with minimal side effects

HOW IT WORKS

HOW IT WORKS

or how a small molecule ligand brings the system to its destination

Through this first-of-a-kind targeted delivery approach, the LC-TDS is hardly taken up by off-target cells, which promises significant dose sparing and potentially fewer side effects.

Cutanos’ LC-TDS differs from all other immunomodulating technologies due to its modular design allowing flexible adaptation for different applications. This further results in a high compatibility with other technologies. Another major advantage is the injury-free administration via the skin through minimally invasive microneedles or microinjectors, which increases application safety and patients compliance.

FIRST OF ITS KIND

FIRST OF ITS KIND

Providing exclusive access to immune cells in the epidermis

Cutanos achieves direct and minimally invasive antigen delivery to Langerhans cells via the skin – No complex and cost-intensive ex vivo loading of dendritic cells (DCs) is required!

Our LC-TDS technology also avoids the disadvantages of antibody-based targeting approaches (e.g. side effects, high production costs and blocking of the receptor for continuous antigen uptake): Due to its design, the LC-TDS mimics a natural pathogen and is processed as such by the Langerhans cells. It can be flexibly combined with various antigens and nanoparticles – often a bottleneck in non-modularly constructed drugs. This gives the LC-TDS a decisive advantage especially in vaccine development against seasonal viral pathogens (e.g. influenza or corona viruses).

WHO WE ARE

WHO WE ARE

THE FOUNDERS AND MANAGEMENT 

Dr. Robert Wawrzinek Co-Founder & CEO

Dr. Robert Wawrzinek

More Infos

Dr. Robert Wawrzinek
Co-Founder & CEO

 

Florian Sparber Head of Tolerance and Autoimmune diseases

Florian Sparber

More Infos

Dr. Florian Sparber
Chief Scientific Officer

Prof. Dr. Christoph Rademacher Co-Founder & Advisor

Prof. Dr. Christoph Rademacher

More Infos

Prof. Dr. Christoph Rademacher
Co-Founder & Advisor

 

Ulrich Platte, MBA CFO & CBO

Ulrich Platte, MBA

More Infos

Ulrich Platte, MBA
CFO

 

THE SCIENTISTS

Federica Quattrone

Federica Quattrone

More Infos

Dr. Federica Quattrone
Head of Inflammation and Infectious diseases

 

Klara Klein Scientist & Project Lead

Klara Klein

More Infos

Dr. Klara Klein
Senior Scientist

Ramona Rîca Scientist

Ramona Rîca, MSc.

More Infos

Ramona Rîca, MSc.
Scientist

#littyjohnson

Dr. Litty Johnson

More Infos

Dr. Litty Johnson
Scientist

Gabriele Carta, MSc.
Research Assistant

Mirza Sarcevic, MSc.
Research Assistant

 

NEWS

NEWS & MEDIA

To get the latest on Cutanos development please refer to our press releases and follow us on LinkedIn and Twitter.

BARDA VITAL Symposium in Berlin

Cutanos Wins BARDA VITAL Prize Challenge for Innovative Vaccine Technology!

 Vienna, Austria (July 1, 2024) – Cutanos GmbH, a biotechnology company based in Vienna, Austria, was awarded first place in the BARDA VITAL Prize (BVP) Challenge, endowed with USD 20,000 by the BARDA Accelerator Network (BAN), at the BARDA VITAL Symposium in Berlin, Germany. Established by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), the BARDA Accelerator Network (BAN) fosters the growth of health security innovation ecosystems globally and accelerates the development and commercialization of next-generation health security solutions. The BARDA VITAL Prize Challenge awards innovative startups and their groundbreaking solutions to potentially make a significant impact on public health.

Cutanos is dedicated to developing next-generation vaccines incorporating its proprietary Langerhans Cell Targeting (LC-TDS) Technology. Looking ahead, the company will increase its efforts towards infectious diseases, capitalizing on the advantages of its technology to boost the efficacy and stability of mRNA vaccines as well as high patient compliance due to pain-free skin administration.

„We are incredibly honored to receive this recognition from BARDA,“ said Robert Wawrzinek, CEO of Cutanos. „This award validates our commitment to develop innovative vaccine technologies that can make a real difference in the fight against infectious diseases. We believe that minimally invasive vaccination will improve vaccine acceptance and accessibility worldwide.“

More information:

BARDA Vital Prize: https://vitalhubhealth.com/prize-challenge/

LinkedIn: https://www.linkedin.com/posts/vital-hub_healthtech-startups-globalhealth-activity-7212488384965988352-F7Gz?utm_source=share&utm_medium=member_desktop

Photo above by VITALHub 

New Team Member

Welcome Ramona Rîca and Litty Johnson, the latest additions to Cutanos‘ science Team!

 

With pleasure we welcome Ramona and Litty and are excited to add even more expertise in immunology and material science to our projects!

New Team Member

We welcome our new

Scientist and Project Lead

Klara Klein

 

We are proud to welcome Klara to our team. With her vast expertise in immunology she is going to lead her own research project and will give valuable impacts in all of Cutanos‘ scientific endeavours!

New Team Member

We welcome our new CFO/CBO Ulrich Platte

The whole team is thrilled to announce Ulrich as our new CFO & CBO. We are beyond confident he will be a major asset to Cutanos and our next business development steps.

Welcome, Ulrich!

Cutanos and Pfizer team up

Cutanos and Pfizer team up to apply LC-TDS technology to autoimmune diseases

 

Thanks to Pfizer’s Emerging Science Fund, Cutanos will explore its immune cell-specific drug delivery system as a potential therapy platform for autoimmune disorders. In the next two years, this joint project aims to show induction of tolerance against self-antigens. Innovative therapeutic solutions in autoimmunity are one of the biggest unmet medical needs worldwide.

New Team Members!

We Welcome our Newest Team Members!

We are very happy to announce our latest additions to the team: Alexandra Sykora (Office Manager), Mirza Sarcevic and Gabriele Carta (Technical Assistants)! Welcome aboard!

Green Labs Austria

Cutanos joins Green Labs Austria Initiative 

As a biotechnology lab Cutanos feels responsible to not only contribute to science but also carrying out experiments in a more sustainable fashion. Hence, we want to participate in Green Labs Austria vision to reduce plastic waste and our carbon footprint. 


www.greenlabsaustria.at

ABA Podcast

ABA Podcast „𝗪𝗶𝗿𝘁𝘀𝗰𝗵𝗮𝗳𝘁 𝗶𝗺 ¾ 𝗧𝗮𝗸𝘁“

 

Doris Dobida talks with Cutanos‘ Co-Founder Robert Wawrzinek about starting a biotech company in Austria.

Webinar Series

Precision NanoSystems Teatime Webinar Series

Robert Wawrzinek talks about: „Small Molecule-Based Targeted Delivery of Nanoparticles to Langerhans Cells in Human Skin“

Publication – ACS central science

A Specific, Glycomimetic Langerin Ligand for Human Langerhans Cell Targeting

Eike-Christian Wamhoff, Jessica Schulze, Lydia Bellmann, Mareike Rentzsch, Gunnar Bachem, Felix F. Fuchsberger, Juliane Rademacher, Martin Hermann, Barbara Del Frari, Rob van Dalen, David Hartmann, Nina van Sorge, Oliver Seitz, Patrizia Stoitzner, Christoph Rademacher

 ACS Central Science (2019), doi.org/10.1021/acscentsci.9b00093

Publication – Biochemistry

A Liposomal Platform for Delivery of a Protein Antigen to Langerin-Expressing Cells

Jessica Schulze, Mareike Rentzsch, Donyoon Kim, Lydia Bellmann, Patrizia Stoitzner, Christoph Rademacher

Biochemistry (2019), doi.org/10.1021/acs.biochem.9b0040

Press Coverage

what the media says about Cutanos (selection)